tetano
Editor, Senior Moderator
Clin Microbiol Infect
. 2021 Jan 19;S1198-743X(21)00031-8.
doi: 10.1016/j.cmi.2021.01.005. Online ahead of print.
Antibody persistence in the first six months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study
Arnaud G L'Huillier[SUP] 1 [/SUP], Benjamin Meyer[SUP] 2 [/SUP], Diego O Andrey[SUP] 3 [/SUP], Isabelle Arm-Vernez[SUP] 4 [/SUP], Stephanie Baggio[SUP] 5 [/SUP], Arnaud Didierlaurent[SUP] 2 [/SUP], Christiane S Eberhardt[SUP] 6 [/SUP], Isabella Eckerle[SUP] 7 [/SUP], Carole Grasset-Salomon[SUP] 8 [/SUP], Angela Huttner[SUP] 9 [/SUP], Klara M Posfay-Barbe[SUP] 10 [/SUP], Irene Sabater Royo[SUP] 2 [/SUP], Jacques A Pralong[SUP] 11 [/SUP], Nicolas Vuilleumier[SUP] 12 [/SUP], Sabine Yerly[SUP] 4 [/SUP], Claire-Anne Siegrist[SUP] 2 [/SUP], Laurent Kaiser[SUP] 7 [/SUP], Geneva Centre for Emerging Viral Diseases
Affiliations
Abstract
Objective: To longitudinally evaluate the persistence of humoral immunity up to six months in a cohort of hospital employees with mild COVID-19.
Methods: We measured anti-RBD, -N and neutralizing antibodies at one, three and six months after mostly mild COVID-19 in 200 hospital workers using commercial ELISAs and a surrogate virus neutralization assay.
Results: SARS-CoV-2-specific antibodies persisted in all participants up to 6 months. Anti-RBD geometric mean concentrations (GMCs) progressively increased between month one (74[SUP].[/SUP]2 U/ml [95%CI 62[SUP].[/SUP]7-87[SUP].[/SUP]8), three (103[SUP].[/SUP]2 U/ml [95%CI 87[SUP].[/SUP]9-121[SUP].[/SUP]2]; p<0[SUP].[/SUP]001), and six (123[SUP].[/SUP]3 U/ml [95%CI 103[SUP].[/SUP]4-147[SUP].[/SUP]0]; p<0[SUP].[/SUP]001) in the whole cohort. Anti-N antibodies were detectable in >97% at all times. Neutralizing antibodies were detectable in 99.5% (195/196) of participants at six months post infection. Their GMC progressively decreased between months one (20[SUP].[/SUP]1 AU/ml [95%CI 16[SUP].[/SUP]9-24[SUP].[/SUP]0]), three (15[SUP].[/SUP]2 AU/ml [95%CI 13[SUP].[/SUP]2-17[SUP].[/SUP]6]; p<0[SUP].[/SUP]001) and six (9[SUP].[/SUP]4 AU/ml [95%CI 7[SUP].[/SUP]7-11[SUP].[/SUP]4]; p<0[SUP].[/SUP]001). RBD-ACE2 inhibiting antibody titers and anti-RBD antibody concentrations strongly correlated at each timepoint (all r>0[SUP].[/SUP]86, p<0[SUP].[/SUP]001). Disease severity was associated with higher initial anti-RBD and RBD-ACE2 inhibiting antibody titers, but not with their kinetics.
Conclusion: Neutralizing antibodies persisted at six months in almost all participants, indicating more durability than initially feared. Anti-RBD antibodies persisted better and even increased over time, possibly related to the preferential detection of progressively higher-affinity antibodies.
. 2021 Jan 19;S1198-743X(21)00031-8.
doi: 10.1016/j.cmi.2021.01.005. Online ahead of print.
Antibody persistence in the first six months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study
Arnaud G L'Huillier[SUP] 1 [/SUP], Benjamin Meyer[SUP] 2 [/SUP], Diego O Andrey[SUP] 3 [/SUP], Isabelle Arm-Vernez[SUP] 4 [/SUP], Stephanie Baggio[SUP] 5 [/SUP], Arnaud Didierlaurent[SUP] 2 [/SUP], Christiane S Eberhardt[SUP] 6 [/SUP], Isabella Eckerle[SUP] 7 [/SUP], Carole Grasset-Salomon[SUP] 8 [/SUP], Angela Huttner[SUP] 9 [/SUP], Klara M Posfay-Barbe[SUP] 10 [/SUP], Irene Sabater Royo[SUP] 2 [/SUP], Jacques A Pralong[SUP] 11 [/SUP], Nicolas Vuilleumier[SUP] 12 [/SUP], Sabine Yerly[SUP] 4 [/SUP], Claire-Anne Siegrist[SUP] 2 [/SUP], Laurent Kaiser[SUP] 7 [/SUP], Geneva Centre for Emerging Viral Diseases
Affiliations
- PMID: 33482352
- DOI: 10.1016/j.cmi.2021.01.005
Abstract
Objective: To longitudinally evaluate the persistence of humoral immunity up to six months in a cohort of hospital employees with mild COVID-19.
Methods: We measured anti-RBD, -N and neutralizing antibodies at one, three and six months after mostly mild COVID-19 in 200 hospital workers using commercial ELISAs and a surrogate virus neutralization assay.
Results: SARS-CoV-2-specific antibodies persisted in all participants up to 6 months. Anti-RBD geometric mean concentrations (GMCs) progressively increased between month one (74[SUP].[/SUP]2 U/ml [95%CI 62[SUP].[/SUP]7-87[SUP].[/SUP]8), three (103[SUP].[/SUP]2 U/ml [95%CI 87[SUP].[/SUP]9-121[SUP].[/SUP]2]; p<0[SUP].[/SUP]001), and six (123[SUP].[/SUP]3 U/ml [95%CI 103[SUP].[/SUP]4-147[SUP].[/SUP]0]; p<0[SUP].[/SUP]001) in the whole cohort. Anti-N antibodies were detectable in >97% at all times. Neutralizing antibodies were detectable in 99.5% (195/196) of participants at six months post infection. Their GMC progressively decreased between months one (20[SUP].[/SUP]1 AU/ml [95%CI 16[SUP].[/SUP]9-24[SUP].[/SUP]0]), three (15[SUP].[/SUP]2 AU/ml [95%CI 13[SUP].[/SUP]2-17[SUP].[/SUP]6]; p<0[SUP].[/SUP]001) and six (9[SUP].[/SUP]4 AU/ml [95%CI 7[SUP].[/SUP]7-11[SUP].[/SUP]4]; p<0[SUP].[/SUP]001). RBD-ACE2 inhibiting antibody titers and anti-RBD antibody concentrations strongly correlated at each timepoint (all r>0[SUP].[/SUP]86, p<0[SUP].[/SUP]001). Disease severity was associated with higher initial anti-RBD and RBD-ACE2 inhibiting antibody titers, but not with their kinetics.
Conclusion: Neutralizing antibodies persisted at six months in almost all participants, indicating more durability than initially feared. Anti-RBD antibodies persisted better and even increased over time, possibly related to the preferential detection of progressively higher-affinity antibodies.